Evidence map›Paper›PMID 23864288›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2013

Phase 1 clinical trials in end-stage cancer: patient understanding of trial premises and motives for participation.

Tove Godskesen, Peter Nygren, Karin Nordin, Mats Hansson, Ulrik Kihlbom

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 3 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 68 citations in OpenAlex.

  1. Qualitative studies on men with prostate cancer: a systematic meta-synthesis.International journal of qualitative studies on health and well-being · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Article
  11. "If only I had", patients' experiences during early oncology trials.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Article
  12. Machine learning models for 180-day mortality prediction of patients with advanced cancer using patient-reported symptom data.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Tove GodskesenCentre for Research Ethics & Bioethics, Uppsala University, Uppsala, Sweden, tove.godskesen@crb.uu.se.
Peter Nygren
Karin Nordin
Mats Hansson
Ulrik Kihlbom
Uppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn cancer, phase 1 clinical trials on new drugs mostly involve patients with advanced disease that is unresponsive to standard therapy. The purpose of this study was to explore the difficult ethical problems related to patient information and motives for participation in such trials.

methodA descriptive and explorative qualitative design was used. Fourteen cancer patients from three different phase 1 trials in end-stage cancer were interviewed. The interviews were analysed using qualitative content analysis.

resultsThe patients expressed unrealistic expectations of therapeutic benefit and inadequate understanding of the trials' purpose, so-called therapeutic misconception. However, they reported a positive attitude towards participation. Thus, the patients valued the close and unique medical and psychological attention they received by participating. Participation also made them feel unique and notable.

conclusionsPatients with end-stage cancer participating in phase 1 clinical trials are unaware of the very small potential for treatment benefit and the risk of harm. Trial participation may offer hope and social-emotional support and a strategy for coping with the emotional stress associated with advanced cancer and may, consequently, improve emotional well-being.

Indexed as

Adaptation, PsychologicalAdultAgedAged, 80 and overAntineoplastic AgentsClinical Trials, Phase I as TopicCross-Sectional StudiesDrug Resistance, NeoplasmFemaleHumansInterviews as TopicMaleMiddle AgedMotivationNeoplasmsPatient ParticipationAntineoplastic Agents

Identifiers

PMID23864288
OpenAlexW2152408155

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.